At its present level of around $200, WST stock is trading at just 5.1x trailing revenue, compared to its five-year average ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

We recently compiled a list of the Weak Earnings, Outlook Drag Shares of These 10 Firms on Thursday. In this article, we are ...

Choreo LLC trimmed its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 5.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange ...

Sudair Pharma aims to localise insulin production, contributing to the continuity of supply and reducing reliance on imports ...

In this process, royalty recipients often face the issue where multiple small future royalty streams cannot fulfill ongoing large lump-sum R&D funding needs. The mismatch is where Royalty Pharma ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

The company reported a loss of Rs 351 crore in the comparable quarter last year, hurt by sluggish sales in India and charges ...

Aside from reciprocal tariffs, US President Trump has teased imposing tariffs on several import heavy sectors, including ...

Indian pharma exporters must unite and report challenges in exports to overcome trade barriers: Raja Bhanu: Shardul Nautiyal, Mumbai Friday, February 14, 2025, 08:00 Hrs [IST] The ...

In a report released today, Laura Chico from Wedbush maintained a Hold rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a ...

Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ("Nxera” or "the Company”; TSE 4565) provides an ...